A Phase 4 interventional study of Probiotic formulation and Placebo in IBS - Irritable Bowel Syndrome, sponsored by Lallemand Health Solutions. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by Lallemand Health Solutions · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Irritable Bowel Syndrome with a site in Turkey — 5 open to participants now, 5 under way, none of them phase 3. Irritable Bowel Syndrome · Turkey.
Among the 21 studies in Irritable Bowel Syndrome with a site in Turkey, this one is the 2nd largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2022, is the only one in phase 4, and was the 5th registered.
1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.
Browse Irritable Bowel Syndrome studies →5 of the 21 studies in Irritable Bowel Syndrome with a site in Turkey are open now. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–45 · Healthy volunteers
Ataturk University · Sites in Turkey
Ages 18–90
Bezmialem Vakif University · Sites in Turkey
Ages 18–70
Istinye University · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 162 is above the median of 70 across 898 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 60 across the 18 interventional studies, 128 across the 3 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
Lallemand Health Solutions is the lead sponsor of 18 studies on the registry; 4 are open to participants now.
Lallemand Health Solutions has 1 study filed under Irritable Bowel Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Irritable Bowel Syndrome with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424898Bezmialem Vakif UniversityLactose Intolerance and Intestinal Permability | 2026-12-15 |
| NCT07870915Saglik Bilimleri UniversitesiRelationship Between Interoception and Postural Control in Constipation-Predominant Irritable Bowel Syndrome | 2027-03-31 |
| NCT07397533Istinye UniversityEffects of Aerobic Exercise and Pain Neuroscience Education in Irritable Bowel Syndrome | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Irritable Bowel Syndrome with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to monitor safety and to evaluate the efficacy of a probiotic formulation on abdominal pain, abnormal defecation, comorbid mood disorders (anxiety and depression) as well as general quality of life in adults with IBS-D.
To monitor safety and to evaluate the efficacy of a probiotic formulation on severity of gastrointestinal symptoms (abdominal pain, abnormal defecation), anxiety, depression and quality of life in adult participants with IBS-D.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this group will be randomized to receive probiotic formulation for the following 8 weeks.
Drug: Probiotic formulation
Participants in this group will be randomized to receive placebo for the following 8 weeks.
Drug: Placebo
Participants will be asked to take 2 doses daily
Participants will be asked to take 2 doses daily
Change in Abdominal Pain
Change in abdominal pain intensity using Visual Analog Scale (VAS) from 0 (no symptom) to 10 (worst possible)
Time frame: 8 weeks
Change in Defecation consistency
Change in abnormal defecation consistency using the Bristol Stool Scale (BSS) from Type 1 (severe constipation) to Type 7 (severe diarrhea)
Time frame: 8 weeks
Change Abdominal pain intensity
Change in abdominal pain intensity using Visual Analog Scale (VAS) from 0 (no symptom) to 10 (worst possible)
Time frame: up to 10 weeks
Abnormal defecation consistency
Change in abnormal defecation consistency using the Bristol Stool Scale (BSS) from Type 1 (severe constipation) to Type 7 (severe diarrhea)
Time frame: up to 10 weeks
Stool frequency
Measured as the average number of stools per week
Time frame: up to 10 weeks
Abdominal discomfort
Using questionnaire in participants diary
Time frame: up to 10 weeks
Perceived Stress
Using the Perceived Stress Scale (PSS) grading from 0 (low stress) to 40 (high perceived stress)
Time frame: 8 weeks
Change in Irritable Bowel Syndrome Symptom Severity Scores
Using the The irritable bowel severity scoring system (IBS-SSS)
Time frame: 8 weeks
Plan to share: No — After publications of the results, de-identified data will be shared with qualified researchers and scientists upon reasonable request to the sponsor including a detailed proposal of the intended use of the data, as per the Lallemand Health Solutions Inc. Policy on Clinical Trial Transparency and Data Sharing (available upon request).
No publications or documents are linked to this record.
Started Aug 2022 (actual). Primary completion is estimated for Nov 2024, 27 months after the start.
Of 24 phase 4 interventional studies under Irritable Bowel Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 29. This study's planned 27 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lallemand Health Solutions